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The human papillomavirus test (HPV) test could improve the (cost ) effectiveness of cervical screening by selecting women with a
very low risk for cervical cancer during a long period. An analysis of a longitudinal study suggests that women with a negative Pap
smear and a negative HPV test have a strongly reduced risk of developing cervical abnormalities in the years following the test, and
that HPV testing lengthens the detectable stage by 2–5 years, compared to Pap smear detection alone.
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One of the possible uses of the human papillomavirus test (HPV) is
in primary cervical cancer screening in addition to or instead of
the current Pap smear (Cuzick et al, 1999a; Cuzick, 2000; Meijer
and Walboomers, 2000).
Introduction of HPV screening should be based on established
(cost-) effectiveness. The (cost-) effectiveness of HPV testing
is primarily determined by the duration of the detectable
preclinical stage (the period from the HPV infection to
clinical disease), and the sensitivity and costs of HPV testing.
To estimate preclinical duration and sensitivity, longitudinal
studies on the association between HPV infection and
the development of neoplasias are necessary. Several large
longitudinal screening studies have started, but no long-
term results have been reported yet, although smaller longitudinal
studies have been published (Rozendaal et al, 1996, 2000; Ho
et al, 1998; Liaw et al, 1999). These studies differ with respect to
HPV test used, age range of women, study design, and cytological
or histological endpoint, which complicates the comparison
and interpretation of these results. It is therefore too
early for definite answers on the value of HPV testing in primary
screening (Myers et al, 2000; Kim et al, 2002; Mandelblatt et al,
2002). However, available data can be explored to derive
preliminary estimates for parameters that determine the
cost-effectiveness of HPV testing. This study investigates
the duration of the detectable preclinical stage using the results
of Rozendaal et al (2000). For these estimates, the 5-year
cumulative incidence of cervical intraepithelial neoplasia
(CIN) III after a negative Pap smear, the current screening interval
in the Netherlands, is compared with the cumulative incidence
within a doubled screening interval of 10 years (Meijer
and Walboomers, 2000) in case of a negative Pap smear and a
negative HPV test.
MATERIAL AND METHODS
The study population, and screening and follow-up results are
described in Rozendaal et al (1996, 2000). Briefly, the smears
obtained during routine screening from 1988 to 1991, from a
cohort of 2250 women aged 34–54 years, who were either normal
or who showed borderline nuclear changes were tested for a high-
risk HPV. The women were followed during a mean period of 6.4
years, using screen-detected (histologically confirmed) CIN III as
end point. Among the 2129 (95%) women with a negative HPV test
at baseline, one case of CIN III was diagnosed at a following
screening round. Of the 121 women with a positive HPV test result
at baseline (5%), 12 women with CIN III were detected later. This
resulted in a relative risk of 210, with a 95% confidence interval
from 27 to 1600.
The disease model used in this study is schematically presented
in Figure 1. Women without cervical disease or HPV may become
infected with HPV. This infection may clear or it may progress to
low-grade CIN. From ‘low-grade CIN’, the disease may regress
spontaneously or progress to high-grade CIN (corresponding with
CIN III), the end point of the model. We assume that CIN III
cannot develop without HPV infection.
In the model, we assumed a constant duration of the HPV
infection, and an exponentially distributed duration of low-grade
CIN with a mean of 6 years. The incidence rate of HPV infections
in the age group considered (34–54 years) was set at five per 1000
woman years (Meijer, 1997). Using the results of the Rozendaal
study, the duration of the HPV infection and the probability that
the HPV infection will progress to CIN III were estimated. On the
basis of these estimates, it was possible to calculate the cumulative
incidence of CIN III within 5 years after the smear was taken; the
current screening interval in the Netherlands, per 1000 cytologi-
cally negative women and the cumulative incidence of CIN III
within 10 years after the smear was taken per 1000 cytologically
negative/HPV negative women.
Initially, it was assumed that there were no diagnostic errors,
that is, the results of the HPV test and the Pap smear as found by
Rozendaal et al (2000) reflected the true disease stage of the
women. We used this as our reference model. In alternative Received 3 February 2003; accepted 15 July 2003
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lmodels, we studied the consequences of assuming diagnostic
errors. We also varied the assumptions on the incidence rate of
HPV infections and the duration of low-grade CIN. The
mathematical description of the model is given in the Appendix.
RESULTS
In Table 1, the results of the reference and alternative models are
shown. Using the reference values for the model parameters, the
duration of HPV infection before progressing to CIN was
estimated at 3.8 years, resulting in a lower cumulative incidence
of CIN III in 10 years for women with double-negative screening
results, than in 5 years after a negative Pap smear and an unknown
HPV result.
Next, we dropped the perfect-test assumptions (100% sensitiv-
ity) of the HPV test and Pap smear separately, by assuming 50%
sensitivity for detecting an HPV infection and 50% sensitivity for
detecting CIN Iþ, respectively. Furthermore, we halved and
doubled our assumptions on the incidence rate of HPV infections
and the duration of low-grade CIN. The estimated range for the
duration of HPV before progressing to CIN widened, from 2 to 5
years. Only where the HPV test was assumed to have a sensitivity
of 50% for HPV infections that will progress to CIN does the
cumulative incidence 10 years after a double-negative result
become slightly higher than the incidence within 5 years after a
negative Pap smear.
DISCUSSION
Our analysis shows duration of the HPV infection before it will
progress into CIN of 2–5 years. For Pap smear screening, the
preclinical duration was the combined duration of CIN and
microinvasive cervical cancer, a period estimated at 15 years on
average (Gustafsson and Adami, 1989; van Oortmarssen and
Habbema, 1991, 1995; van Oortmarssen et al, 1992; Zielinski et al,
2001). Consequently, adding the HPV test to primary screening
leads to duration of the detectable preclinical stage of almost 20
years in women aged 34–54 years. Furthermore, the 10-year
cumulative incidence in women with a negative Pap smear and
HPV test was lower than the 5-year cumulative incidence in
women with a negative Pap smear and an unknown HPV result.
This high negative predictive value of CIN III in double-negative
women is the result of a longer preclinical duration and a better
selection of women, as women with double-negative test results are
at a lower risk of cervical cancer than women with only negative
Pap smear results of whom part will have HPV infections.
These results suggest that an HPV test, in combination with the
Pap smear, can considerably lengthen the screening interval in
double-negative women (Meijer and Walboomers, 2000).
The confidence interval around the relative risk found by
Rozendaal et al (1996) was large (from 27 to 1600). The
upperbound of the confidence interval results in an HPV infection
duration of 5.5 years. Assuming a relative risk corresponding to
the lowerbound, results in a negligible duration. Even then, the 10-
year cumulative incidence in double-negative women is lower than
the 5-year cumulative incidence in women with a negative
cytological result, assuming no diagnostic errors. This results
from the very low risk of double-negative women of becoming
infected with HPV infected, and subsequently developing cervical
abnormalities in the years following the test. More firm estimates
will be obtained on the basis of the results of the ongoing
longitudinal studies.
The relative risks found in other studies (Ho et al, 1998; Liaw
et al, 1999), 10.0 and 12.7, respectively, are lower than the range
studied here. One of the reasons may be that the other studies
concern women aged around 20 years. In young women, the
occurrence of HPV infections is high (Melkert et al, 1993) and a
much higher proportion of these infections are transient (Evander
et al, 1995) compared to older women. Therefore, adding the HPV
test in primary screening is not useful for young women (Cuzick
et al, 1999b).
With the current model, it is technically not possible to lower
the sensitivity of the HPV test and Pap smear simultaneously.
Doing this will probably result in an estimate for the duration of
the HPV infection of around 2 years. Also, the assumption of a
constant duration of the HPV infection can be dropped using a
more sophisticated model. However, these refinements pay off
only when adequate longitudinal data on HPV detection are
available for quantification of the additional parameters.
Women may develop CIN III without first passing the stages
CIN I (and even CIN II). This situation has been represented by
assuming a relatively short average duration of low-grade CIN of 2
years. Together with the assumption that this stage is exponentially
distributed among women, this leads to a situation in which part of
the women will develop CIN III shortly after having no neoplasia.
Under these assumptions, the duration of the HPV infection before
progressing to CIN is estimated to be relatively long, and the
selection of low-risk women by adding HPV to cytology will be
even better (incidence of CIN III 2.2 vs 4.5, Table 1).
The end point of the model was CIN III as imposed by the data.
Invasive cancer is the end point to be preferred as prevention of
invasive cancer and therefore, death is aimed at by cervical cancer
screening. This end point, however, does not yield sufficient power
due to the low risk for invasive cancer in Pap smear screened
women, unless extremely large and long-term trials are performed.
The current estimate on the duration of HPV before developing
CIN is a combined estimate for the duration of HPV for women
who will have a regressive CIN III lesion and those who will
progress to cervical cancer. To solve the uncertainty on the
confounding of regressive CIN III lesions, this prospective analysis
with CIN III as end point should be accompanied by archival
studies, in which retrospectively the HPV status of smears
preceding a diagnosis of cervical cancer, is assessed. Zielinski
et al (2001) concluded in a retrospective study of 57 women with
invasive cervical cancer that the detectable preclinical stage could
be prolonged by at least 2 years by adding HPV testing, which
corroborates our results. This type of study, however, is
susceptible to confounding biases such as selection and length
time bias, which may result in an underestimation of the extension
of the detectable preclinical stage as cervical cancers found after
participation in a screening programme may be selective towards
fast-growing cancers.
Doubling the screening interval for double-negative women will
result in cost savings, as half of the screening rounds can be
omitted. If, for example, the effectiveness of 10-yearly combined
screening is the same as 5-yearly screening using the Pap smear,
the costs of adding the HPV test to the Pap smear must be lower
than these savings to be at least a cost-equal alternative. For a full
cost analysis, other costs and savings should also be taken into
account, such as the costs of follow-up in HPV positive/
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Figure 1 Schematic representation of the natural history model for HPV
and CIN. IHPV¼incidence rate of HPV infections in women without
cervical disease or HPV, PCIN¼probability that HPV will progress to CIN III,
DHPV¼duration of HPV infection preceding CIN and DCIN¼duration of
CIN I/II preceding CIN III.
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decrease in the detection of regressive cervical lesions because of a
longer screening interval.
In conclusion, adding the HPV test to cytology in primary
screening for cervical cancer results in an additional duration of
the detectable preclinical stage of 2–5 years. Consequently, the
screening interval for women with cytological and HPV-negative
test results may be considerably lengthened. These results remain
to be confirmed by the large longitudinal studies that are currently
underway.
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Appendix
Mathematical formulae of the reference model
If we assume that:
  incidence rate of HPV is IHPV,
  probability that HPV will progress to CIN III is PCIN,
  duration of HPV preceding CIN is DHPV and
  duration CIN I/II preceding CIN III is exponentially distributed
with mean DCIN.
Then, cumulative incidence of CIN III after x years for
women without cervical lesions and without HPV infection at
Table 1 Estimated values for the duration of HPV, the probability that the HPV infection will progress to CIN III, the 5-year cumulative incidence in
women with a negative smear and the 10-year cumulative incidence in women with a negative smear and a negative HPV test
Duration HPV
(years)
Probability HPV
progresses to CIN III
5-year cum. incidence CIN III
after cyt  (per 1000 women)
10-year cum. incidence CIN III
after cyt /HPV-(per 1000 women)
Reference model
a 3.8 0.19 4.1 2.2
Sensitivity HPV test for HPV 50%
b 2.2 0.08 4.6 5.2
Sensitivity cytology for CIN I+ 50% 3.5 0.16 10.0c 4.0
c
Incidence HPV infections 0.0025 2.3 0.17 4.5 1.4
Incidence HPV infections 0.010 4.7 0.20 3.8 3.7
Mean duration CIN I/II 2 years 4.3 0.11 4.5 2.2
Mean duration CIN I/II 10 years 3.6 0.27 4.0 2.2
aReference model: mean duration CIN I/II 6 years, sensitivity HPV test for HPV infection 100%, sensitivity cytology for CIN I+100% and incidence HPV infections 0.005 per
woman year.
b Assuming that the one woman that developed CIN III in (Rozendaal et al, 2000) after HPV negative test at baseline did not have a false-negative HPV test result.
c Owing a limited sensitivity of cytology for CIN III, only part of these lesions will be detected within the follow-up period considered.
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CHPV ðxÞ¼IHPVPCIN
Z x DHPV
0
ð1   e y 1=DCIN I IIÞdy
Cumulative incidence of CIN III after x years for women without
cervical lesions but with HPV infection at baseline
CHPVþðxÞ¼ IHPVPCIN
Z x DHPV
0
ð1   e y 1=DCIN I IIÞdy
þ PCIN
1
DHPV
Z X
x DHPV
ð1   e y 1=DCIN I IIÞdy
Relative risk on CIN III in women not having a cervical lesion but
being HPV infected compared to women without cervical lesion
and HPV infection after x years
rrðxÞ¼
CHPVþðxÞ
CHPV ðxÞ
¼
IHPV
R x DHPV
0
ð1 e y 1=DCIN I IIÞdyþ 1
DHPV
R X
x DHPV
ð1 e  y 1=DCIN I IIÞdy
IHPV
R x DHPV
0
ð1   e y 1=DCIN I IIÞdy
Cumulative incidence of CIN III x years after not having a cervical
lesion
IðxÞ¼pHPV CHPV ðxÞþpHPVþCHPVþðxÞ
with pHPV  and pHPVþ the percentage of women without and with
HPV infection at baseline, respectively.
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